Kansas Agricultural Experiment Station Research Reports
Volume 0
Issue 1 Cattleman's Day (1993-2014)

Article 1565

2007

Effects of SRP Vaccine in Reducing E. coli O157:H7 in Cattle
A. B. Thornton
Kansas State University

D. U. Thomson
Kansas State University, Manhattan, dthomson@vet.k-state.edu

J. T. Fox
Kansas State University

See next page for additional authors

Follow this and additional works at: https://newprairiepress.org/kaesrr
Part of the Other Animal Sciences Commons

Recommended Citation
Thornton, A. B.; Thomson, D. U.; Fox, J. T.; Loneragan, G. H.; Burkhardt, D.; and Nagaraja, T. G. (2007)
"Effects of SRP Vaccine in Reducing E. coli O157:H7 in Cattle," Kansas Agricultural Experiment Station
Research Reports: Vol. 0: Iss. 1. https://doi.org/10.4148/2378-5977.7513
This report is brought to you for free and open access by New
Prairie Press. It has been accepted for inclusion in Kansas
Agricultural Experiment Station Research Reports by an
authorized administrator of New Prairie Press. Copyright 2007
Kansas State University Agricultural Experiment Station and
Cooperative Extension Service. Contents of this publication
may be freely reproduced for educational purposes. All other
rights reserved. Brand names appearing in this publication are
for product identification purposes only. No endorsement is
intended, nor is criticism implied of similar products not
mentioned. K-State Research and Extension is an equal
opportunity provider and employer.

Effects of SRP Vaccine in Reducing E. coli O157:H7 in Cattle
Abstract
Cattle are the main reservoir of Escherichia coli O157:H7, which is a foodborne pathogen that causes
bloody diarrhea in adults and kidney damage in children . E. coli O157 is shed in the feces of cattle, which
can be a contamination source of water, ground beef, fresh vegetables, and unpasterized milk and fruit
juices. In 2003, shiga-toxin producing E. coli O157:H7 caused 73,000 illnesses, which resulted in over
2,000 hospitalizations and 60 deaths in the United States. The estimated annual cost of this illness was
$405 million, which included $370 million for premature deaths, $30 million for medical care, and $5
million for lost productivity. Strategies to reduce this food borne illness must be further investigated.
A new vaccine technology targeting E. coli O157:H7 in hopes of reducing the colonization of this
pathogen in beef cattle has been developed (Epitopix, LLC, Wilmar, MN). This vaccine was designed to
block the transport of iron into the bacterial cell, which is an essential nutrient needed for the survival of
this microorganism. Previous trials showed that this vaccine elicited an immune response and reduced
fecal shedding of the pathogen in five-month old Holstein steers. The purpose of this experiment was to
further evaluate the efficacy of this new siderophore receptor/porin protein (SRP) technology by analyzing
fecal shedding and immune responses of mixed-breed calves orally inoculated with E. coli O157:H7.
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EFFECTS OF SRP VACCINE IN REDUCING E. COLI O157:H7 IN CATTLE
A.B. Thornton1, D.U. Thomson1, J.T. Fox1, G.H. Loneragan2,
D. Burkhardt3, and T. G. Nagaraja1

five-month old Holstein steers. The purpose of this experiment was to further
evaluate the efficacy of this new
siderophore receptor/porin protein (SRP)
technology by analyzing fecal shedding
and immune responses of mixed-breed
calves orally inoculated with E. coli
O157:H7.

Introduction
Cattle are the main reservoir of Escherichia coli O157:H7, which is a foodborne pathogen that causes bloody diarrhea in adults and kidney damage in children . E. coli O157 is shed in the feces of
cattle, which can be a contamination
source of water, ground beef, fresh vegetables, and unpasterized milk and fruit
juices. In 2003, shiga-toxin producing E.
coli O157:H7 caused 73,000 illnesses,
which resulted in over 2,000 hospitalizations and 60 deaths in the United States.
The estimated annual cost of this illness
was $405 million, which included $370
million for premature deaths, $30 million
for medical care, and $5 million for lost
productivity. Strategies to reduce this food
borne illness must be further investigated.

Experimental Procedures
Thirty beef calves (3 to 4 months old)
that were pre-tested and shown to be free
of E. coli O157:H7, were processed and
allowed to acclimatize as a herd at a local
Manhattan, Kansas farm. Calves were
treated with One Shot Ultra 7, Bovi-Shield
Gold 5, Micotil 300, and Dectomax.
Calves were fed a starter ration at approximately 7 lbs per head per day and
had ad libitum access to water and brome
grass hay.

A new vaccine technology targeting E.
coli O157:H7 in hopes of reducing the
colonization of this pathogen in beef cattle
has been developed (Epitopix, LLC, Wilmar, MN). This vaccine was designed to
block the transport of iron into the bacterial cell, which is an essential nutrient
needed for the survival of this microorganism. Previous trials showed that this vaccine elicited an immune response and reduced fecal shedding of the pathogen in

Approximately one month after arrival,
calves were placed into one of two treatment groups and administered either the
SRP vaccine or the placebo on day 0 of the
trial. Twenty-one days after the first injection was administered, the calves were revaccinated and transported to a BL-2 facility where they were confined to individual
pens and allowed to acclimatize for one
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are illustrated in Figures 1-5. From day 11
to day 35 post challenge, there was a decrease (P<0.04) in fecal shedding of E.
coli O157:H7 over time when the “SRP”
treatment group was compared to the control group. There was no significant difference between the two treatment groups
when evaluating the concentration of the
bacteria using the RAMS (rectoanal mucosal swab) sampling technique. There was a
difference (P<0.05), however, when the
prevalence in both the fecal and RAMS
samples were combined (Figure 3), showing that there were twice as many positive
samples in the control group when compared to the “SRP” treatment group by day
32 post challenge.

week. On day 36, calves from both treatment groups were orally inoculated with a
mixture of five strains of E. coli O157:H7,
which were made resistant to nalidixic
acid.
Cattle fecal samples and rectoanal mucosal swab (RAMS) samples were collected once a day for five consecutive days
after oral challenge and then sampled three
times a week for the following five weeks.
Blood samples were collected on day 1,
just prior to vaccination, and at weekly
intervals to monitor antibody response to
SRP vaccination in calves. At the end of
the study, calves were euthanized and
samples were taken from the rumen, omasum, abomasum, cecum, colon, and rectum, along with tissue samples from the
gall bladder mucosa and the rectoanal mucosa, to determine the presence and concentration of E. coli O157:H7. Detection
of this microorganism was performed by
transferring each sample to a selective enrichment broth, by making serial 10-fold
dilutions to allow for quantification of the
microorganism, and by transferring each
dilution to a selective agar containing
nalidixic acid to simplify detection of the
challenge organism. Further antigenic
testing was performed to confirm proper
identification of the microorganism, and
concentration of the bacteria from each
sample was calculated.

The necropsy data also illustrated the
efficacy of this vaccine showing the mean
proportion of samples testing positive in
the SRP treatment group were less
(P<0.01) than those found positive in the
non-vaccinate control group. The SRP
vaccinate group had higher (P<0.01) concentrations of anti SRP antibodies compared to the control group.
Implications
Overall, vaccination of calves with the
SRP vaccine reduced the prevalence of E.
coli O157:H7 in cattle. This not only defines a new potential strategy to reducing
food borne illness, but also increases the
consumer’s confidence when purchasing
quality meat.

Results and Discussion
The presence and concentration of E.
coli O157:H7 in the two treatment groups
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Figure 1 Average Percent of Animals Positive with NalR E. coli O157:H7 from Day
11 Post Challenge to the Day of Necropsy.
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Figure 2 NalR E. coli O157:H7 Positive Cattle in Either the Fecal or Rectoanal
Mucosal Swabs Samples from Day 11 Post Challenge to the Day of Necropsy
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Figure 3 Average Fecal Concentration of NalR E. coli O157:H7 in Cattle from the
Day of Challenge to the Day of Necropsy
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Figure 4 The Number of Animals from Each Treatment Group that had NalR E.
coli O157:H7 Present in the Selected Sampling Site
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Figure 5 Calves’ Immunological Responses from the Day the First Vaccination was
Administered to the Day of Challenge.
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